Barclays Increases Hologic, Inc. (HOLX) Price Target to $42.00
The firm currently has an "equal weight" rating on the stock. Barclays' price objective indicates a potential upside of 14.91% from the stock's previous close.
from Biotech News
The firm currently has an "equal weight" rating on the stock. Barclays' price objective indicates a potential upside of 14.91% from the stock's previous close.
The most important thing is to improve and not stop. Even if you have taken some course, this does not mean that you are now a guru. You need to constantly practice, learn something new.
0 Comments